Full-Time

Data Scientist in Responsible AI

Posted on 10/22/2025

Deadline 11/1/25
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

Hybrid

Hybrid role requiring 50% onsite in Madrid; remote work not applicable.

Category
Data & Analytics (1)
Required Skills
Microsoft Azure
Python
Machine Learning
AWS
Requirements
  • 5+ years working with advanced machine learning algorithms
  • At least 1 year of hands-on experience with Generative AI
  • Experience in responsible AI practices
  • Advanced proficiency in Python
  • Cloud knowledge
  • Familiarity with responsible AI frameworks and tools
  • Deep understanding of model evaluation techniques, including performance, bias, toxicity, explainability, transparency, cost/value
  • Strong background in statistics, machine learning algorithms, and optimization techniques
  • Feature Engineering and Prompt engineering
  • Deployment experience with cloud platforms (AWS, Azure) and machine learning workbenches for robust and scalable productization
  • Excellent analytical skills and the ability to tackle complex challenges with innovative solutions
  • Strong verbal and written communication skills
  • Hold a B.Sc., B.Eng., M.Sc., M.Eng., Ph.D., or D.Eng. in Computer Science, Physics, Statistics, Mathematics, or an equivalent degree
  • Be fluent in English
  • Be based in or near Madrid, with availability to work in a hybrid model (50% onsite)
  • Be willing to work at a time consistent with CET and ET time zones
Responsibilities
  • Responsible AI Development: Collaborate with data scientists, AI engineers, developers, AI experts, AI product owners, and stakeholders (e.g., legal, security, quality, ethics) to integrate responsible AI principles into scalable and robust applications, ensuring ethical AI deployment and compliance with regulatory standards
  • Automated AI risk evaluations: Design, develop, and integrate tools that support the automated evaluation of risks in LLM Models and AI solutions
  • Compliance and Risk Management: develop automated frameworks and tools to support compliance and risk management at scale
  • Performance Evaluation: Implement and refine techniques to evaluate the accuracy of AI outputs, promoting value consideration in AI solutions
  • Bias Mitigation: Implement and refine techniques to identify, mitigate, and monitor biases in AI outputs, promoting fairness and inclusivity in AI applications
  • Understanding of Roche’s Ethical Principles: Develop tools and frameworks to integrate Roche’s ethical principles into the development and deployment of AI solutions
  • Exploratory Data Analysis (EDA): Perform thorough data exploration to understand the behavior of different AI models and solutions. Synthesize information scientifically using statistical and visualization techniques to support recommendations
  • Software Development: Apply software development best practices, including unit testing, CI/CD pipelines, ensuring robust logging, experiment tracking, and model monitoring
  • Stakeholder Communication: Translate complex technical results into clear, actionable insights for stakeholders, driving data-driven decision-making across the organization
Desired Qualifications
  • Experience with Generative AI projects
  • Experience with responsible AI practices (preferred)
  • Familiarity with responsible AI frameworks and tools (advantage)
  • Experience communicating results to non-technical audiences (advantage)
  • Experience deploying AI solutions at scale (advantage)

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI can strengthen AI pathology workflows and biomarker discovery.
  • Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
  • Nurix collaboration deepens Roche's reach into protein degradation and hematology.

What critics are saying

  • Swiss franc strength keeps distorting reported growth and investor perception.
  • Patent expirations on older medicines force rapid replacement from newer assets.
  • CT-388 must beat Novo Nordisk and Eli Lilly to matter.

What makes Roche unique

  • Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech integration made Roche the world's largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE